Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of May 1, 2024, the Compensation Co
Vor BiopharmaMay 3 00:00 ET
Express News | Vor Biopharma Inc - on April 30, Board Increased Size of Board From Six to Seven Members
ReutersMay 2 16:47 ET
Vor Biopharma Welcomes Oncology Expert to Board of Directors
TipRanksMay 2 16:27 ET
Press Release: Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to Its Board of Directors
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR),
Dow JonesMay 2 16:01 ET
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to Its Board of Directors
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board o
Vor BiopharmaMay 2 00:00 ET
Express News | Wedbush Reiterates Outperform on Vor Biopharma, Maintains $11 Price Target
Moomoo 24/7Apr 23 13:24 ET
Buy Rating Affirmed for Vor Biopharma on Clinical Progress and Market Potential
TipRanksApr 12 13:25 ET
12 Health Care Stocks Moving In Friday's After-Market Session
GainersLongeveron (NASDAQ:LGVN) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by
BenzingaApr 5 16:31 ET
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming i
Vor BiopharmaApr 1 00:00 ET
Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation
Yahoo FinanceMar 29 06:09 ET
PLAB, SMTC and WOOF Are Among After Hour Movers
Seeking AlphaMar 28 16:52 ET
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Inotiv (NOTV) and Vericel (VCEL)
TipRanksMar 26 08:50 ET
Stifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)
TipRanksMar 25 22:05 ET
Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)
TipRanksMar 24 21:50 ET
MASI, PLRX and CGC Are Among After Hour Movers
Seeking AlphaMar 22 16:59 ET
JMP Securities Reiterates Market Outperform on Vor Biopharma, Maintains $12 Price Target
JMP Securities analyst Silvan Tuerkcan reiterates Vor Biopharma with a Market Outperform and maintains $12 price target.
Analyst UpgradesMar 22 13:13 ET
Analysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Vor Biopharma (VOR)
TipRanksMar 22 00:30 ET
Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating
Vor Biopharma (VOR) has an average buy rating and a price target range of $10 to $22, according to analysts polled by Capital IQ. Price: 1.86, Change: +0.06, Percent Change: +3.33
MT NewswiresMar 21 09:49 ET
Vor Biopharma Is Maintained at Buy by Stifel
Vor Biopharma Is Maintained at Buy by Stifel
Dow JonesMar 21 09:49 ET
Vor Biopharma Price Target Maintained With a $11.00/Share by Wedbush
Vor Biopharma Price Target Maintained With a $11.00/Share by Wedbush
Dow JonesMar 21 09:20 ET
No Data
No Data